Patient characteristics
| Characteristic . | N (%) . |
|---|---|
| n | 70 (100) |
| age (mean [SD]) | 56.80 (13.99) |
| Gender | |
| Female | 28 (40.0) |
| Male | 42 (60.0) |
| Disease | |
| Leukemia | 33 (47.1) |
| Myelodysplastic syndrome | 13 (18.6) |
| Myeloproliferative disorder | 4 (5.8) |
| Non-Hodgkin lymphoma | 15 (21.4) |
| Other | 5 (7) |
| Conditioning intensity | |
| Myeloablative | 23 (32.9) |
| Reduced intensity | 42 (60.0) |
| Nonablative | 5 (7.1) |
| Conditioning regimen∗ | |
| Fludarabine/melphalan | 36 (51.4) |
| Busulfan/fludarabine | 14 (20.0) |
| Fludarabine/melphalan/thiotepa | 5 (7.1) |
| Other (containing TBI) | 12 (16.8) |
| Other (TBI-free) | 3 (4.2) |
| Degree of HLA match | |
| Matched unrelated | 42 (60.0) |
| Matched related | 16 (22.8) |
| Mismatched/haplo-related | 7 (10) |
| Mismatched unrelated | 5 (7.1) |
| Acute GVHD (before day 100) | |
| No | 30 (42.9) |
| Yes | 40 (57.1) |
| Characteristic . | N (%) . |
|---|---|
| n | 70 (100) |
| age (mean [SD]) | 56.80 (13.99) |
| Gender | |
| Female | 28 (40.0) |
| Male | 42 (60.0) |
| Disease | |
| Leukemia | 33 (47.1) |
| Myelodysplastic syndrome | 13 (18.6) |
| Myeloproliferative disorder | 4 (5.8) |
| Non-Hodgkin lymphoma | 15 (21.4) |
| Other | 5 (7) |
| Conditioning intensity | |
| Myeloablative | 23 (32.9) |
| Reduced intensity | 42 (60.0) |
| Nonablative | 5 (7.1) |
| Conditioning regimen∗ | |
| Fludarabine/melphalan | 36 (51.4) |
| Busulfan/fludarabine | 14 (20.0) |
| Fludarabine/melphalan/thiotepa | 5 (7.1) |
| Other (containing TBI) | 12 (16.8) |
| Other (TBI-free) | 3 (4.2) |
| Degree of HLA match | |
| Matched unrelated | 42 (60.0) |
| Matched related | 16 (22.8) |
| Mismatched/haplo-related | 7 (10) |
| Mismatched unrelated | 5 (7.1) |
| Acute GVHD (before day 100) | |
| No | 30 (42.9) |
| Yes | 40 (57.1) |
Haplo, haploidentical; SD, standard deviation; TBI, total body irradiation.
No patients received antithymocyte globulin as in vivo T-cell depletion.